Back to search results

Specimen Collection for Liquid Biopsy Development in Non-Hematologic Cancer

This study is collecting blood and tumor tissue samples from people with non-hematologic cancer (cancers that don't start in blood-forming tissues like bone marrow or lymph nodes). The goal is to develop a new, less invasive "liquid biopsy" test that uses next-generation sequencing (NGS) to detect cancer. You can join if you are 18 or older, have a non-hematologic cancer with tumor in your body, and have either tumor tissue available for testing or previous genomic test results from your tumor. The main goal is to collect these samples from the time of your cancer diagnosis through up to 5 years of follow-up care. The study is currently unclear about its recruitment status.

Study design
This is an observational study designed to collect samples from up to 3000 participants. It is a multicenter, longitudinal study, meaning it takes place at multiple locations and follows participants over time.
What's involved
You would provide whole blood samples at a baseline visit and then periodically for up to 5 years, following your doctor's standard care schedule. Tumor tissue from any cancer recurrences would also be collected.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 5 years after cancer diagnosis during their standard-of-care follow-up visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02586389

Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

Recruiting
Not specifiedAges 18+Observational
Sequenom, Inc.
~3,000 participants
Updated 2024-10-16 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
biospecimen sample collection for liquid biopsy assay development
Measured over After cancer diagnosis through 5 years of standard of care follow-up visits

Conditions

Non-hematologic Cancer

Explore related trials

Solid Neoplasm

NCT02586389

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Idaho Urology

    Boise, Idahono site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sue Beruti, MD · STUDY_DIRECTOR · Sequenom, Inc.

Who to contact

Graham McLennan
[email protected]
(858) 202-9162
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject is 18 years of age or older;
Subject is willing to provide written informed consent;
Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either;
Subject is able, in the professional opinion of the investigator, to provide whole blood at the Baseline Visit and at the Interim Visits.

Exclusion

Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit.
Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit.
Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up).
Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.

What this trial measures

  • biospecimen sample collection for liquid biopsy assay developmentAfter cancer diagnosis through 5 years of standard of care follow-up visits

    Analysis of circulating tumor DNA (ctDNA) in whole blood will be compared to baseline tumor DNA for concordance of mutations related to cancer.